The agreement will deploy Insilico’s Pharma AI platform across Takeda’s pipeline to accelerate early-stage drug discovery and candidate selection.

The acquisition adds first-in-class BK polyomavirus candidate potravitug as Ipsen continues an aggressive week of dealmaking following its Kartos Therapeutics takeover.

The reverse merger will create Nasdaq-listed Cortigent Holdings, providing Vivani's brain-computer interface business with independent funding to accelerate vision restoration and neurorehabilitation technologies.

Acquisition centres on Yupelri COPD franchise while retaining upside through respiratory and legacy pipeline assets.

Late-stage myelofibrosis candidate navtemadlin could reshape treatment for patients with suboptimal responses to Jakafi.

Merck KGaA has agreed to acquire US-based life sciences company Bio-Techne, significantly expanding its presence across the life sciences value chain.

Biogen has agreed to acquire RayThera in a deal worth up to $1 billion, strengthening its position in immunology and adding a portfolio of small-molecule anti-inflammatory candidates to its development pipeline.

cAMPfield Therapeutics has emerged from stealth with $180 million in Series A funding to advance a next-generation oral PDE4 inhibitor targeting inflammatory bowel disease (IBD), a space where earlier drugs have struggled due to tolerability limitations.

Kardigan has made a strong public market entrance, with shares jumping more than 37% on its first day of trading following a $400 million initial public offering that underscores continued investor appetite for biotech listings.

Merck & Co. has strengthened its commitment to AI-driven drug discovery through a new multi-year partnership with Protillion Biosciences, signing a deal worth up to $510 million focused on identifying and engineering novel therapeutic candidates.

A new biotech focused exclusively on migraine treatment has emerged with significant financial backing and a leadership team responsible for some of the most important advances in migraine medicine over the last decade.

Jazz Pharmaceuticals has expanded its oncology pipeline through a new collaboration with AbCellera, signing a deal worth more than $2.4 billion.

Eli Lilly has signed a licensing deal worth up to $1bn with Swedish biotech AlzeCure Pharma for ACD680, a preclinical Alzheimer’s programme targeting amyloid-beta production via gamma-secretase modulation.

GSK has agreed to acquire Nuvalent in a $10.6bn all-cash transaction, bringing a trio of late-stage lung cancer assets into its oncology portfolio and marking one of the company’s largest strategic moves in over a decade.

Roche has struck a deal worth up to $2.3bn with Nurix Therapeutics to co-develop and co-commercialise bexobrutideg (NX-5948), an oral BTK degrader targeting B-cell malignancies, immunology, and neurology.

ResMed has completed its $340m acquisition of Noctrix Health, adding a newly approved neurostimulation therapy for restless leg syndrome (RLS) to its growing sleep medicine portfolio.

Alnylam Pharmaceuticals has entered a collaboration worth up to $2bn with Inceptive Nucleics, combining RNA interference (RNAi) drug development expertise with generative AI models specifically designed for sequence-based medicines.

Eli Lilly and Ascidian Therapeutics have entered into a multi-year strategic collaboration worth up to $1.9bn, focused on developing RNA exon-editing therapies for undisclosed monogenic kidney diseases.

The partnership expands a global co-development model spanning ADCs, multispecific antibodies, and early-stage oncology assets across US and China markets.

The acquisition combines diagnostic imaging scale with growing AI capabilities as healthcare investors target data-rich clinical infrastructure.